Editorial: DNA methylation-based fecal biomarkers for the noninvasive screening of GI cancers

Future Oncology

Volumn 6, Issue 3, 2010, Pages 333-336

  Goel, Ajay ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; DNA; K RAS PROTEIN; PROTEIN NDRG4; PROTEIN P53; PROTEIN RASSF2; PROTEIN TFPI2; SECRETED FRIZZLED RELATED PROTEIN 2; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 5; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER MORTALITY; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DNA METHYLATION; DNA SCREENING; EARLY DIAGNOSIS; EDITORIAL; FECES ANALYSIS; HUMAN; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; CHEMISTRY; FECES; GASTROINTESTINAL TUMOR; GENETICS; MASS SCREENING; METHODOLOGY;

DNA METHYLATION; FECES; GASTROINTESTINAL NEOPLASMS; HUMANS; MASS SCREENING; TUMOR MARKERS, BIOLOGICAL;

EID: 77949442659     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.9     Document Type: Editorial

References (16)

1. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat. Rev. Cancer 4(2), 143-153 (2004).
2. Jones PA, Baylin SB: The epigenomics of cancer. Cell 128(4), 683-692 (2007).
3. Sidransky D: Emerging molecular markers of cancer. Nat. Rev. Cancer 2(3), 210-219 (2002).
4. Laird PW: The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3(4), 253-266 (2003).
5. Nagasaka T, Goel A, Matsubara N, Tanaka N: Detection of fecal DNA methylation for colorectal neoplasia: does it lead to an optimal screening test? Acta Med. Okayama 60(5), 249-256 (2006).
6. Nagasaka T, Tanaka N, Cullings HM et al.: Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J. Natl Cancer Inst. 101(18), 1244-1258 (2009).
7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
8. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med. 351(26), 2704-2714 (2004).
9. Zou H, Taylor WR, Harrington JJ et al.: High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 136(2), 459-470 (2009).
10. Graser A, Stieber P, Nagel D et al.: Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 58(2), 241-248 (2009).
11. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat. Genet. 21(2), 163-167 (1999).
12. Ushijima T: Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 5(3), 223-231 (2005).
13. Chen WD, Han ZJ, Skoletsky J et al.: Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl Cancer Inst. 97(15), 1124-1132 (2005).
14. Glockner SC, Dhir M, Yi JM et al.: Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 69(11), 4691-4699 (2009).
15. Melotte V, Lentjes MH, van den Bosch SM et al.: N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J. Natl Cancer Inst. 101(13), 916-927 (2009).
16. Hellebrekers DM, Lentjes MH, van den Bosch SM et al.: GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin. Cancer Res. 15(12), 3990-3997 (2009).